Review Article
Herbal Medicinal Products from Passiflora for Anxiety: An Unexploited Potential
Table 1
List of clinical trials related to the use of Passiflora to treat anxiety registered in NIH.
| Trial number | Dosage form | Formulation NAME | Stage | Period | Reference anxiolytic AGENT | Status |
| NCT00794456 | Tablet | Pasalix: Passiflora incarnata L., Crataegus oxyacantha L., Salix alba L. | Phase 3 | 6 weeks | Valeriana officinalis L. (50 mg) | Completed Oct 2013 | NCT01178632 | Tablet | Passiflorine: Passiflora incarnata L., Crataegus oxyacantha L., Salix alba L. | Phase 3 | 4 weeks | Valeriana officinalis L. | Unknown | NCT00944268 | Liquid | Passiflora incarnata L., Crataegus oxyacantha L., Salix alba L. | Phase 3 | 30 days | None | Unknown | NCT02065843 | Capsules | Passiflora incarnata L. 100 mg | Phase 2 phase 3 | 1 h before dental surgery | Midazolam (15 mg) | Completed Sep 2014 | NCT03909906 | tablets | Euphytose®: 50 mg Valeriana officinalis L., 40 mg Passiflora incarnata L., 10 mg Crataegus sp., 10 mg Ballota nigra L. | Not applicable | 14 days | None | Completed Dec 2019 | NCT00997490 | Film-coated sugar-pill | Neurapas balance: hypericum, valerian, passionflower | Phase 3 | 6 weeks | None | Completed Feb 2003 |
|
|
|